These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
152 related articles for article (PubMed ID: 38034435)
1. Natural History of Pediatric Patients With Crohn's Disease Treated With Mesalamine Therapy. Young DD; Perry S; Malay S; Sferra TJ; Finkler M; Moses J JPGN Rep; 2023 Nov; 4(4):e379. PubMed ID: 38034435 [TBL] [Abstract][Full Text] [Related]
2. Natural history of children with mild Crohn's disease. Sharma Y; Bousvaros A; Liu E; Bender Stern J World J Gastroenterol; 2019 Aug; 25(30):4235-4245. PubMed ID: 31435176 [TBL] [Abstract][Full Text] [Related]
3. No Benefit of Continuing 5-Aminosalicylates in Patients with Crohn's Disease Treated with Anti-metabolite Therapy. Picetti D; Kim J; Zhu W; Sandborn WJ; Jairath V; Singh S Dig Dis Sci; 2022 Jul; 67(7):3115-3123. PubMed ID: 34797442 [TBL] [Abstract][Full Text] [Related]
4. Azathioprine and 6-mercaptopurine for maintenance of surgically-induced remission in Crohn's disease. Gordon M; Taylor K; Akobeng AK; Thomas AG Cochrane Database Syst Rev; 2014 Aug; 2014(8):CD010233. PubMed ID: 25081347 [TBL] [Abstract][Full Text] [Related]
5. Oral 5-aminosalicylic acid for maintenance of surgically-induced remission in Crohn's disease. Gjuladin-Hellon T; Gordon M; Iheozor-Ejiofor Z; Akobeng AK Cochrane Database Syst Rev; 2019 Jun; 6(6):CD008414. PubMed ID: 31220875 [TBL] [Abstract][Full Text] [Related]
7. Aminosalicylates for induction of remission or response in Crohn's disease. Lim WC; Wang Y; MacDonald JK; Hanauer S Cochrane Database Syst Rev; 2016 Jul; 7(7):CD008870. PubMed ID: 27372735 [TBL] [Abstract][Full Text] [Related]
8. Stopping 5-aminosalicylates in patients with ulcerative colitis starting biologic therapy does not increase the risk of adverse clinical outcomes: analysis of two nationwide population-based cohorts. Ungaro RC; Limketkai BN; Jensen CB; Allin KH; Agrawal M; Ullman T; Colombel JF; Jess T Gut; 2019 Jun; 68(6):977-984. PubMed ID: 30420398 [TBL] [Abstract][Full Text] [Related]
9. Cost-Effectiveness of 5-Aminosalicylate Therapy in Combination With Biologics or Tofacitinib in the Treatment of Ulcerative Colitis. Shaffer SR; Huang E; Patel S; Rubin DT Am J Gastroenterol; 2021 Jan; 116(1):125-133. PubMed ID: 32947317 [TBL] [Abstract][Full Text] [Related]
10. Comparison of outcomes of continuation/discontinuation of 5-aminosalicylic acid after initiation of anti-tumor necrosis factor-alpha therapy in patients with inflammatory bowel disease. Choi YI; Kim TJ; Park DK; Chung JW; Kim KO; Kwon KA; Kim YJ Int J Colorectal Dis; 2019 Oct; 34(10):1713-1721. PubMed ID: 31471699 [TBL] [Abstract][Full Text] [Related]
11. Clinical and endoscopic outcomes of patients with colonic Crohn's disease treated with 5-aminosalicylates as monotherapy. Castillo-Regalado E; Ríos R; Aràjol C; Gely C; Márquez L; Calafat M; González-Muñoza C; Cañete F; Mesonero F; Guardiola J; Garcia-Planella E; Mañosa M; Domènech E Gastroenterol Hepatol; 2023 Mar; 46(3):164-170. PubMed ID: 36179946 [TBL] [Abstract][Full Text] [Related]
12. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. Feagan BG; Macdonald JK Cochrane Database Syst Rev; 2012 Oct; 10():CD000543. PubMed ID: 23076889 [TBL] [Abstract][Full Text] [Related]
13. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. Wang Y; Parker CE; Bhanji T; Feagan BG; MacDonald JK Cochrane Database Syst Rev; 2016 Apr; 4(4):CD000543. PubMed ID: 27101467 [TBL] [Abstract][Full Text] [Related]
14. Real-world assessment of therapy changes, suboptimal treatment and associated costs in patients with ulcerative colitis or Crohn's disease. Rubin DT; Mody R; Davis KL; Wang CC Aliment Pharmacol Ther; 2014 May; 39(10):1143-55. PubMed ID: 24697826 [TBL] [Abstract][Full Text] [Related]
15. No benefit of continuing vs stopping 5-aminosalicylates in patients with ulcerative colitis escalated to anti-metabolite therapy. Singh S; Kim J; Zhu W; Dulai PS; Sandborn WJ; Jairath V Aliment Pharmacol Ther; 2020 Aug; 52(3):481-491. PubMed ID: 32573825 [TBL] [Abstract][Full Text] [Related]
16. Aminosalicylates for induction of remission or response in Crohn's disease. Lim WC; Hanauer S Cochrane Database Syst Rev; 2010 Dec; (12):CD008870. PubMed ID: 21154400 [TBL] [Abstract][Full Text] [Related]
17. Concomitant 5-Aminosalicylate Therapy in Moderate-to-Severe Ulcerative Colitis Patients Escalated to Infliximab Is Not Beneficial. Balram B; Joshi H; Wong K; Kroeker KI; Dieleman LA; Halloran BP; Baumgart DC; Peerani F Dig Dis Sci; 2021 Nov; 66(11):3985-3992. PubMed ID: 33184796 [TBL] [Abstract][Full Text] [Related]